LLY

1,160.14

+2.66%↑

JNJ

231.99

-0.28%↓

ABBV

222.4

-2.17%↓

UNH

404.23

+0.98%↑

MRK

119.9

-0.85%↓

LLY

1,160.14

+2.66%↑

JNJ

231.99

-0.28%↓

ABBV

222.4

-2.17%↓

UNH

404.23

+0.98%↑

MRK

119.9

-0.85%↓

LLY

1,160.14

+2.66%↑

JNJ

231.99

-0.28%↓

ABBV

222.4

-2.17%↓

UNH

404.23

+0.98%↑

MRK

119.9

-0.85%↓

LLY

1,160.14

+2.66%↑

JNJ

231.99

-0.28%↓

ABBV

222.4

-2.17%↓

UNH

404.23

+0.98%↑

MRK

119.9

-0.85%↓

LLY

1,160.14

+2.66%↑

JNJ

231.99

-0.28%↓

ABBV

222.4

-2.17%↓

UNH

404.23

+0.98%↑

MRK

119.9

-0.85%↓

Home・Listă Acțiuni・United Therapeutics Corp

United Therapeutics Corp

Deschisă

SectorSănătate

547.2 -0.03

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

543.92

Maxim

551.34

Indicatori cheie
By Trading Economics
Venit	-89M 275M
Vânzări	-8.7M 782M
P/E Medie Sector	20.134 49.888
EPS	5.82
Marjă de profit	35.176
Angajați	1,400
EBITDA	-176M 348M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+21.1% upside

Dividende
By Dow Jones
Următoarele câștiguri	29 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-1.5B 23B
Deschiderea anterioară	547.23
Închiderea anterioară	547.2

Sentimentul știrilor

By Acuity

50%

139 / 344 Clasament în Healthcare

United Therapeutics Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 iun. 2026, 19:20 UTC

Principalele dinamici ale pieței

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

7 iun. 2026, 23:46 UTC

Market Talk

Nikkei Likely to Fall After U.S. Tech Selloff -- Market Talk

7 iun. 2026, 23:36 UTC

Market Talk

Oil Prices Rise Amid Escalating Supply Disruption Concerns -- Market Talk

7 iun. 2026, 18:00 UTC

Câștiguri

Inflation Readings, Oracle Earnings, the SpaceX IPO, and More to Watch This Week -- Barrons.com

6 iun. 2026, 12:40 UTC

Achiziții, Fuziuni, Preluări

Correction to Texas Billionaires Article America's Resort -- WSJ

6 iun. 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

6 iun. 2026, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

6 iun. 2026, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 iun. 2026, 00:14 UTC

Achiziții, Fuziuni, Preluări

4 Arm Execs Sold $26 Million in Stock, but They Missed a High -- Barrons.com

5 iun. 2026, 21:27 UTC

Câștiguri

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 iun. 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5 iun. 2026, 20:20 UTC

Achiziții, Fuziuni, Preluări

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 iun. 2026, 20:19 UTC

Achiziții, Fuziuni, Preluări

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 iun. 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 iun. 2026, 19:26 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 iun. 2026, 19:26 UTC

Market Talk

Hog Futures Tumble to Close Week -- Market Talk

5 iun. 2026, 19:10 UTC

Market Talk

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 iun. 2026, 19:03 UTC

Market Talk

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 iun. 2026, 18:59 UTC

Market Talk

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 iun. 2026, 18:47 UTC

Market Talk

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 iun. 2026, 18:34 UTC

Market Talk

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 iun. 2026, 18:33 UTC

Achiziții, Fuziuni, Preluări

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 iun. 2026, 17:50 UTC

Câștiguri

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 iun. 2026, 17:27 UTC

Market Talk

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 iun. 2026, 16:48 UTC

Achiziții, Fuziuni, Preluări

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 iun. 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 iun. 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

5 iun. 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

5 iun. 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Comparație

Modificare preț

United Therapeutics Corp Așteptări

Obiectiv de preț

By TipRanks

21.1% sus

Prognoză pe 12 luni

Medie 665.9 USD 21.1%

Maxim 738 USD

Minim 516 USD

În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruUnited Therapeutics Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

10 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 10 analiști care au acordat evaluări ale acțiunilor United Therapeutics Corp - Dist în ultimele 3 luni.

Sentiment

By Acuity

139 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.